Andrew Spencer

28PUBLICATIONS
172CO-AUTHORS
Molecular targetsGene and molecular therapyCancer therapy (excl. chemotherapy and radiation therapy)Predictive and prognostic markersApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (28)

|Sep 16, 2026
Toxicity-Related Treatment Cessation in Newly Diagnosed Multiple Myeloma-Risk Factors and Survival: An Analysis From the APAC and ANZ Myeloma and Related Diseases Registry.

|Mar 02, 2026
Efficacy and Safety of Belantamab Mafodotin with Bortezomib plus Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma: The DREAMM-6 Arm B Trial.

Rakesh Popat, Bradley Augustson, Paul Cannell

|Jul 28, 2025
CLOX and neurotox: Utility of the clock drawing task in monitoring for immune effector cell-associated neurotoxicity syndrome following chimeric antigen receptor T-cell therapy.

Christina Kazzi, Ty Simpson, Miriam Wronski

|Jun 09, 2025
International Myeloma Society/International Myeloma Working Group Consensus Recommendations on the Definition of High-Risk Multiple Myeloma.

Hervé Avet-Loiseau, Faith E Davies, Mehmet K Samur

|Jun 03, 2025
Isatuximab Subcutaneous by On-Body Injector Versus Isatuximab Intravenous Plus Pomalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma: Phase III IRAKLIA Study.

Sikander Ailawadhi, Ivan Špička, Andrew Spencer

|Nov 04, 2024
Preventing Allogeneic Stem Cell Transplant-Related Cardiovascular Dysfunction: ALLO-Active Trial.

Hayley T Dillon, Nicholas J Saner, Tegan Ilsley

Pageof 5

Frequent Collaborators

6 joint publications

Hang Quach

6 joint publications

Simon J Harrrison

5 joint publications

Phoebe Joy Ho

4 joint publications

Elizabeth Moore